• Effect of DPP-4 Inhibition on the Vasculature A review of experimental studies evaluating some of the mechanistic effects of DPP-4 inhibition on the vasculature.
   
• Antiplatelet Therapy and T2DM A population-based cohort study evaluates dual antiplatelet use after ACS in patients with and without diabetes.
   
• Glucose Lowering Trials: Lessons Learned Addresses several controversial topics related to CV risk and antihyperglycemic therapy.
   
• TECOS and ELIXA Updates Examine clinical trial updates from the TECOS and ELIXA outcome studies.
   

• Effect of SGLT2 Inhibition on the Vasculature Explore antiatherogenic effects of SGLT2 inhibition in a mouse model of T1DM and T2DM.
   
• Therapeutic Inertia and CV Consequences Investigate CV consequences of therapeutic inertia for glycemic and blood pressure control in T2DM.
   
• EMPA-REG OUTCOME: CV Outcomes Review several of the CV outcome highlights from the landmark EMPA-REG OUTCOME trial.
   

• CV Risk and Sulfonylurea Use An appraisal of multiple clinical studies investigating the relationship between SUs and CV risk for patients with T2DM.
   
• Efficacy and Safety of Antihyperglycemic Therapy Explore liraglutide use during Ramadan and CV safety data from the basal insulin lispro development program.
   
• EMPA-REG OUTCOME: Safety Appraise safety data from the landmark EMPA-REG OUTCOM

Nyhetsinfo

www red DiabetologNytt